US major Johnson & Johnson reiterated on Monday that it has applied for Emergency Use Authorization of its single-dose Covid-19 vaccine in India.
Earlier on Monday, the company had said that it remained committed to bringing its single-dose Covid-19 vaccine to India and looks forward to ongoing discussions with the Indian government.
The US FDA authorised Johnson & Johnson's viral vector Covid-19 vaccine for emergency use in February this year. However, weeks after its authorisation, the vaccine was linked to a rare but serious blood-clotting disorder.
Last month, Europe's medicines regulator added a rare nerve-degenerating disorder, Guillain-Barré syndrome, as a possible rare side effect from Johnson & Johnson's Covid-19 vaccine after it reviewed 108 cases reported worldwide.
If J&J's vaccine gets approval in India, it will be the second foreign-made vaccine to be approved in the country, after Moderna.